-
Drug Repurposing Targeting COVID-19 3CL Protease using Molecular Docking and Machine Learning Regression Approach
Authors:
Imra Aqeel,
Abdul Majid
Abstract:
The COVID-19 pandemic has initiated a global health emergency, with an exigent need for effective cure. Progressively, drug repurposing is emerging a promise solution as it saves the time, cost and labor. However, the number of drug candidates that have been identified as being repurposed for the treatment of COVID-19 are still insufficient, so more effective and thorough drug exploring strategies…
▽ More
The COVID-19 pandemic has initiated a global health emergency, with an exigent need for effective cure. Progressively, drug repurposing is emerging a promise solution as it saves the time, cost and labor. However, the number of drug candidates that have been identified as being repurposed for the treatment of COVID-19 are still insufficient, so more effective and thorough drug exploring strategies are required. In this study, we joint the molecular docking with machine learning regression approaches to find some prospective therapeutic candidates for COVID-19 treatment. We screened the 5903 approved drugs for their inhibition by targeting the main protease 3CL of SARS-CoV-2, which is responsible to replicate the virus. Molecular docking is used to calculate the binding affinities of these drugs to the main protease 3CL. We employed several machine learning regression approaches for QSAR modeling to find out some potential drugs with high binding affinities. Our outcomes demonstrated that the Decision Tree Regression (DTR) model with best scores of R2 and RMSE, is the most suitable model to explore the potential drugs. We shortlisted six favorable drugs. These drugs have novel repurposing potential, except for one antiviral ZINC203757351 compound that has already been identified in other studies. We further examined the physiochemical and pharmacokinetic properties of these most potent drugs and their best binding interaction to specific target protease 3CLpro. Our verdicts contribute to the larger goal of finding effective cures for COVID-19, which is an acute global health challenge. The outcomes of our study provide valuable insights into potential therapeutic candidates for COVID-19 treatment.
△ Less
Submitted 23 June, 2024; v1 submitted 25 May, 2023;
originally announced May 2023.
-
Hybrid Approach to Identify Druglikeness Leading Compounds against COVID-19 3CL Protease
Authors:
Imra Aqeel,
Abdul Majid
Abstract:
SARS-COV-2 is a positive single-strand RNA-based macromolecule that has caused the death of more than 6.3 million people since June 2022. Moreover, by disturbing global supply chains through lockdown, the virus has indirectly caused devastating damage to the global economy. It is vital to design and develop drugs for this virus and its various variants. In this paper, we developed an in-silico stu…
▽ More
SARS-COV-2 is a positive single-strand RNA-based macromolecule that has caused the death of more than 6.3 million people since June 2022. Moreover, by disturbing global supply chains through lockdown, the virus has indirectly caused devastating damage to the global economy. It is vital to design and develop drugs for this virus and its various variants. In this paper, we developed an in-silico study-based hybrid framework to repurpose existing therapeutic agents in finding drug-like bioactive molecules that would cure Covid-19. We employed the Lipinski rules on the retrieved molecules from the ChEMBL database and found 133 drug-likeness bioactive molecules against SARS coronavirus 3CL Protease. Based on standard IC50, the dataset was divided into three classes active, inactive, and intermediate. Our comparative analysis demonstrated that the proposed Extra Tree Regressor (ETR) based QSAR model has improved prediction results related to the bioactivity of chemical compounds as compared to Gradient Boosting, XGBoost, Support Vector, Decision Tree, and Random Forest based regressor models. ADMET analysis is carried out to identify thirteen bioactive molecules with ChEMBL IDs 187460, 190743, 222234, 222628, 222735, 222769, 222840, 222893, 225515, 358279, 363535, 365134 and 426898. These molecules are highly suitable drug candidates for SARS-COV-2 3CL Protease. In the next step, the efficacy of bioactive molecules is computed in terms of binding affinity using molecular docking and then shortlisted six bioactive molecules with ChEMBL IDs 187460, 222769, 225515, 358279, 363535, and 365134. These molecules can be suitable drug candidates for SARS-COV-2. It is anticipated that the pharmacologist/drug manufacturer would further investigate these six molecules to find suitable drug candidates for SARS-COV-2. They can adopt these promising compounds for their downstream drug development stages.
△ Less
Submitted 24 August, 2022; v1 submitted 3 August, 2022;
originally announced August 2022.
-
Drug Repurposing For SARS-COV-2 Using Molecular Docking
Authors:
Imra Aqeel,
Abdul Majid,
Muhammad Ismail,
Hina Bashir
Abstract:
Drug repurposing is an unconventional approach that is used to investigate new therapeutic aids of existing and shelved drugs. Recent advancement in technologies and the availability of the data of genomics, proteomics, transcriptomics, etc., and with the accessibility of large and reliable database resources, there are abundantly of opportunities to discover drugs by drug repurposing in an effici…
▽ More
Drug repurposing is an unconventional approach that is used to investigate new therapeutic aids of existing and shelved drugs. Recent advancement in technologies and the availability of the data of genomics, proteomics, transcriptomics, etc., and with the accessibility of large and reliable database resources, there are abundantly of opportunities to discover drugs by drug repurposing in an efficient manner. The recent pandemic of SARS-COV-2, that caused the death of 6,245,750 human beings to date, has tremendously increase the exceptional usage of bioinformatics tools in interpreting the molecular characterizations of viral infections. In this paper, we have employed various bioinformatics tools such as AutoDock-Vina, PyMol etc. We have found a leading drug candidate Cepharanthine that has shown better results and effectiveness than recently used antiviral drug candidates such as Favipiravir, IDX184, Remedesivir, Ribavirin and etc. This paper has analyzed Cepharanthine potential therapeutic importance as a drug of choice in managing COVID-19 cases. It is anticipated that proposed study would be beneficial for researchers and medical practitioners in handling SARS-CoV-2 and its variant related diseases.
△ Less
Submitted 26 July, 2022; v1 submitted 2 June, 2022;
originally announced June 2022.
